Heart Failure: History and Discovery

Heart failure is one of the oldest recognized disorders in medicine, but it was understood for most of human history through its outward signs rather than its cause. For more than three thousand years it was known by the swelling it produced — dropsy, the generalized waterlogging of the body — and by the breathlessness that came with it. No single physician discovered heart failure. Instead, its modern understanding was assembled piece by piece: ancient Egyptian, Greek, Indian, and Roman observers described the swelling and the breathlessness; William Harvey's De Motu Cordis (1628) established the heart as a pump; William Withering's Account of the Foxglove (1785) gave medicine its first carefully studied drug for the condition; Otto Frank and Ernest Starling explained how the failing pump behaves; and the twentieth century revealed that heart failure is driven by the body's own hormones, opening the door to the treatments used today. This page traces that long, cumulative discovery and is careful to mark where understanding was hypothesis rather than fact.

Dropsy: The Ancient Face of Heart Failure
Greek, Roman, and Ayurvedic Medicine
Avicenna, Ibn al-Nafis, and the Road to Circulation
William Harvey and the Heart as a Pump (1628)
William Withering and the Foxglove (1785)
The Frank–Starling Law of the Heart
Bloodletting, “Congestive” Heart Failure, and the Hemodynamic Era
The Neurohormonal Revolution and Modern Therapy
A Discovery Without a Single Discoverer
Research Papers and References
Connections

Dropsy: The Ancient Face of Heart Failure

For most of recorded history, what we now call heart failure was seen and named not as a disease of the heart but as a disease of water. The word physicians used for thousands of years was dropsy — from the Greek hydrops, “water” — meaning the visible, generalized swelling of the legs, abdomen, and face caused by fluid building up in the tissues. We now recognize that swelling as one of the cardinal signs of a failing heart, but to ancient observers it was the illness itself. Crucially, dropsy is a sign, not a single disease: it can also arise from kidney and liver disease, so ancient descriptions of dropsy capture heart failure without isolating it. That ambiguity is part of the story, and an honest history must keep it in view.

The oldest surviving medical evidence comes from ancient Egypt. The Ebers Papyrus, dated to roughly 1550 BCE, and other Egyptian medical texts describe patients with the combination of features that modern cardiologists would immediately recognize as congestive heart failure: breathlessness on exertion, an inability to lie flat, swelling of the body, and a weak, irregular pulse. Egyptian physicians, working within a religious and humoral worldview rather than a circulatory one, are also credited with one of the first deliberate treatments aimed at the swelling — bloodletting — in an attempt to draw off what they perceived as an excess of fluid. They did not know the heart was the cause; they treated what they could see.

It is worth stating plainly what these ancient records do and do not show. They demonstrate that the clinical picture of heart failure — edema and breathlessness together — is ancient and was carefully observed across several great civilizations. They do not show that anyone in antiquity understood the heart as a failing pump; that understanding lay more than three thousand years in the future. The continuity that matters here is one of observation: human beings have suffered from, and described, the syndrome of heart failure for as long as we have written records of medicine.

Back to Table of Contents

Greek, Roman, and Ayurvedic Medicine

The classical Mediterranean inherited and refined the ancient description of dropsy. The Hippocratic writers of Greece (around the fifth and fourth centuries BCE) described dropsical patients in detail and interpreted the swelling within the theory of the four humours — the idea that health depended on a balance of blood, phlegm, yellow bile, and black bile. Dropsy was understood as an imbalance and accumulation of fluid, often blamed on the liver or spleen, and a Hippocratic aphorism grimly observed that dropsy appearing after certain illnesses carried a poor prognosis — an early, accurate clinical intuition that the swelling signaled deep trouble, even though its cardiac origin was unknown.

Roman medicine carried this tradition forward. Aulus Cornelius Celsus and later the enormously influential Galen of Pergamon (second century CE) wrote on dropsy and its management with diuretic regimens, dietary measures, and bloodletting. Galen's model of the body, however, embedded a fundamental error that would constrain medicine for some fourteen hundred years: he taught that blood was continuously manufactured in the liver and consumed in the tissues, ebbing and flowing rather than circulating, and that the heart warmed and distributed it. Within that framework, a failing circulatory pump was literally inconceivable. The Roman world also knew the foxglove plant and is sometimes said to have used Digitalis in folk preparations, though the plant's specific, documented application to dropsy belongs to the much later work of Withering.

Independently, the Ayurvedic tradition of ancient India described conditions of generalized swelling and breathlessness — often discussed under Sanskrit terms such as shvayathu or shotha (swelling/edema) and shwasa (breathlessness/dyspnea) — and treated them with herbal and dietary regimens within its own theoretical system of bodily humours (the doshas). As with the Egyptian and Greek records, the Ayurvedic descriptions show a sophisticated clinical recognition of the heart-failure syndrome without the modern circulatory explanation. Across three separate civilizations, then, the same picture was seen and recorded — convergent observation of a syndrome whose mechanism would remain hidden until the seventeenth century.

Back to Table of Contents

Avicenna, Ibn al-Nafis, and the Road to Circulation

The bridge between ancient observation and modern understanding was built largely in the medieval Islamic world, which preserved, criticized, and extended Greek medicine. The Persian physician Avicenna (Ibn Sina), in his Canon of Medicine (completed around 1025 CE), systematized cardiac and pulse diagnosis and is credited with explicitly connecting breathlessness and certain pulse abnormalities to disorders of the heart — an important conceptual step that began, tentatively, to link the outward signs back toward the organ itself.

A still more decisive step came from the Arab physician Ibn al-Nafis of Damascus and Cairo, who in the thirteenth century (around 1242 CE) described the pulmonary circulation — the passage of blood from the right side of the heart through the lungs and back to the left side. In doing so he directly contradicted Galen's claim that blood passed through invisible pores in the wall between the heart's two ventricles. This was a genuine and remarkable discovery, though for centuries it was little known in the West and did not immediately overturn the prevailing model. Historians continue to debate how much it influenced later European anatomists; what is not in doubt is that the correct description existed, in writing, four hundred years before Harvey.

These medieval contributions matter to the history of heart failure because the concept of a failing pump is impossible without first establishing that the heart is a pump driving a circulation. Avicenna tied symptoms to the heart; Ibn al-Nafis got the lesser (pulmonary) circuit right. The full, demonstrated account of the blood's circulation — and with it the conceptual foundation on which all later understanding of heart failure rests — would arrive with William Harvey in 1628.

Back to Table of Contents

William Harvey and the Heart as a Pump (1628)

In 1628 the English physician William Harvey (1578–1657) published a slim seventy-two-page Latin treatise, Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus (“An Anatomical Exercise on the Motion of the Heart and Blood in Animals”), universally known as De Motu Cordis. In it Harvey demonstrated, through dissection, measurement, ligature experiments, and simple arithmetic, that the blood moves in a closed circuit, driven around the body by the heart acting as a mechanical pump. He showed that the heart fills passively and contracts actively to expel blood, and he calculated that the sheer volume the heart pumps each hour was far too large for blood to be continuously made and consumed as Galen had taught — it had to be the same blood, circulating.

This was a true revolution in physiology. By replacing Galen's ebb-and-flow model with a circulating system powered by a pump, Harvey provided — for the first time — the conceptual framework within which “heart failure” could even be defined. If the heart is a pump that circulates blood, then a heart that pumps inadequately, allowing pressure and fluid to back up into the lungs and tissues, becomes an intelligible idea. Harvey himself did not work out the pathophysiology of heart failure; that was not his project, and it would take centuries more. But every later advance in understanding the failing heart is downstream of his demonstration that the heart is a pump and the blood circulates.

It is fair to note that Harvey's achievement built on predecessors — the pulmonary circuit of Ibn al-Nafis and the renewed European anatomy of figures such as Realdo Colombo and Andrea Cesalpino — and that some elements of circulation had been glimpsed before him. What Harvey supplied that no one before had was rigorous experimental and quantitative proof assembled into a single, coherent, and ultimately irresistible argument. For that reason De Motu Cordis is rightly regarded as the foundation stone, and 1628 as a genuine turning point in the long story of heart failure.

Back to Table of Contents

William Withering and the Foxglove (1785)

If Harvey gave heart failure its concept, the English physician and botanist William Withering (1741–1799) gave it its first scientifically studied treatment. In 1785 Withering published An Account of the Foxglove, and Some of Its Medical Uses; with Practical Remarks on Dropsy, and Other Diseases. According to a now-famous account, Withering had learned that an old Shropshire herbalist's secret family remedy for dropsy worked, and he reasoned that the active ingredient among its many herbs was the purple foxglove, Digitalis purpurea. Over roughly a decade he investigated it methodically.

What makes Withering's work a landmark of scientific pharmacology — and not merely another herbal recommendation — is its rigor. He reported a large case series of his own patients (commonly cited as 156 to 163 cases) treated with foxglove for dropsy, recording successes and failures honestly. He worked out that the drug was effective in small doses, identified its dangerous toxic effects (nausea, vomiting, visual disturbance, and a slowed, irregular pulse), described how potency varied with the plant's preparation and the season of harvest, and urged caution and careful dosing — an early and explicit appeal for prudence in adopting a new medicine. Digitalis acts on the heart, increasing the force of contraction and helping the failing pump clear the accumulated fluid of dropsy, although Withering himself attributed its benefit chiefly to its diuretic (water-removing) action and did not fully grasp its cardiac mechanism.

Digitalis (digoxin) descended directly from Withering's foxglove and remained a mainstay of heart-failure treatment for more than two centuries; it is still used in selected patients today, particularly for rate control in atrial fibrillation coexisting with heart failure. Equally important, Withering's careful, dose-aware, outcome-recording method is often cited as one of the earliest models of evidence-based clinical pharmacology. His 1785 book stands as one of the great bridges between traditional herbal medicine and modern scientific therapeutics.

Back to Table of Contents

The Frank–Starling Law of the Heart

Understanding why a heart fails required understanding the rules by which a healthy heart adjusts its output, and those rules were worked out in the laboratory around the turn of the twentieth century. The result is enshrined in the Frank–Starling law of the heart, named for two physiologists who studied the relationship between how much the heart muscle is stretched by incoming blood and how forcefully it then contracts. In simple terms: within limits, the more the heart fills, the harder it pumps.

The German physiologist Otto Frank (1865–1944) laid the experimental groundwork, publishing results in 1895 from studies on the isolated frog heart that related the tension the heart muscle developed to the degree to which it was stretched beforehand. The English physiologist Ernest Henry Starling (1866–1927) and his collaborators extended the principle to the intact mammalian heart in a series of experiments and papers in the years around 1912–1914, and Starling gave it its enduring public statement in his Linacre Lecture of 1915, published in 1918. The law is therefore correctly dated to two contributions: Frank in 1895 and Starling in 1915/1918.

Honesty about priority matters here, and the historical literature is explicit about it: neither Frank nor Starling was the first to observe that the heart's filling governs its output. Earlier investigators had noted versions of the relationship, and the eponym “Frank–Starling” honors the two men who characterized and popularized it rather than crediting them as sole discoverers. The law's relevance to heart failure is profound: the failing heart operates on a depressed version of this curve, and the body's attempt to compensate by retaining fluid to stretch the heart further is exactly what produces the congestion — the dropsy — that defined the disease for the ancients. The old sign and the modern physiology finally met.

Back to Table of Contents

Bloodletting, “Congestive” Heart Failure, and the Hemodynamic Era

The bridge from the failing-pump concept to the modern clinical term ran through a long era in which heart failure was understood mainly as a problem of plumbing and pressure. Because the visible problem was fluid backing up and congesting the lungs, liver, and legs, the syndrome came to be called congestive heart failure (CHF) — a name describing the congestion that results when the heart cannot keep the circulation moving forward. The term remains in wide everyday use, though many cardiologists now prefer simply “heart failure,” since congestion is one feature of a broader disorder and is not always present.

For centuries the dominant treatment for the congestion was the same one the Egyptians had reached for: bloodletting, along with leeches and purging, to physically remove fluid and “unload” the overfull circulation. Remarkably, although it was practiced for the wrong theoretical reasons, venesection does transiently reduce the volume the heart must handle, and a modern cardiologist can see a faint logic in it — an accidental forerunner of the diuretics and venodilators used today. Bloodletting for dropsy persisted into the nineteenth century before fading as physiology advanced.

The twentieth century brought the tools to study heart failure as a hemodynamic disorder: cardiac catheterization made it possible to measure pressures and flows inside the living heart, the electrocardiograph and later the chest X-ray and echocardiogram allowed the failing heart to be characterized in life, and the landmark Framingham Heart Study (begun in 1948) defined heart failure's clinical criteria and risk factors in a large population. Within this hemodynamic framework, treatment aimed at the numbers — using diuretics to remove fluid, vasodilators to ease the load, and inotropic drugs to push the pump harder. That last strategy, however, would expose the limits of thinking about heart failure as mere plumbing, and set the stage for a conceptual revolution.

Back to Table of Contents

The Neurohormonal Revolution and Modern Therapy

The decisive modern insight is that chronic heart failure is not only a pump problem but a whole-body hormonal disorder. When the heart's output falls, the body responds as if to blood loss: it activates the sympathetic nervous system (adrenaline) and the renin–angiotensin–aldosterone system (RAAS), which constrict blood vessels and make the kidneys retain salt and water. In the short term this defends blood pressure, but sustained over months and years this neurohormonal activation is toxic to the heart — it drives fluid retention (the old dropsy), raises the load on the failing muscle, and promotes harmful remodeling of the heart itself. This is the neurohormonal hypothesis of heart failure, and it should be named as the hypothesis it began as: a reframing, proposed and then progressively confirmed across the 1980s and 1990s, that overturned the older purely hemodynamic view.

The clinical proof was as striking as the idea. Drugs that block these hormonal systems — rather than simply whipping the heart to pump harder — were shown to make patients live longer. The watershed was the CONSENSUS-1 trial, published in 1987, which demonstrated that the ACE inhibitor enalapril (a drug that blocks the RAAS) significantly reduced mortality in severe heart failure. Beta-blockers, drugs that blunt the sympathetic system and had once been considered dangerous in heart failure, were subsequently proven in large trials of the 1990s to reduce death further still, and mineralocorticoid-receptor antagonists (which block aldosterone) added another survival benefit. Together these formed the neurohormonal foundation of modern heart-failure therapy.

Tellingly, the same logic completes the circle back to Withering: digitalis from the foxglove, the eighteenth-century remedy for dropsy, turns out to have a mild beneficial effect on neurohormonal activation as well, one modern thread among many in its long history. Heart-failure therapy has continued to evolve — with angiotensin receptor–neprilysin inhibitors, SGLT2 inhibitors originally developed for diabetes, implantable devices, and other advances — but the central twentieth-century discovery, that blocking the body's own compensatory hormones protects the failing heart, remains the organizing principle of treatment today.

Back to Table of Contents

A Discovery Without a Single Discoverer

The history of heart failure is, more than almost any other disease, a story of cumulative discovery rather than a single eureka moment. There is no one person who “discovered” heart failure, and any account that names a sole discoverer is wrong. The syndrome was observed and described independently by Egyptian, Greek, Indian, and Roman physicians thousands of years ago under the name dropsy; its mechanism became thinkable only when Harvey proved the heart is a pump in 1628; its first carefully studied drug came from Withering's foxglove in 1785; the rules of the failing pump were worked out by Frank, Starling, and their predecessors around 1900; and its true nature as a neurohormonal, whole-body disorder was uncovered only in the late twentieth century.

Seen this way, the long persistence of the word dropsy is the thread that ties the whole history together. The ancients treated the swelling because the swelling was all they could see. The moderns treat the swelling too — but now they understand it as the downstream consequence of a failing pump and the body's own counterproductive hormonal response, and they have drugs that target the cause rather than only the sign. Each generation added a piece: observation, then circulation, then pharmacology, then physiology, then molecular and hormonal understanding.

That cumulative, self-correcting character is exactly what makes the history of heart failure a model of how medicine actually advances. Knowledge moved forward through many hands across many centuries and cultures, with each contributor building on, and sometimes correcting, those before. For anyone living with heart failure today, the practical lesson of this history is hopeful: the treatments now available rest on three thousand years of accumulated human effort to understand a disease that was, for most of that time, only a mystery of water and breath.

Back to Table of Contents

Research Papers and References

The references below combine peer-reviewed historical reviews of heart failure with curated PubMed topic-search links into the historical and ethnopharmacological literature. Historical primary texts — the Ebers Papyrus, the Hippocratic corpus, Galen, Avicenna's Canon, Ibn al-Nafis, Harvey's De Motu Cordis (1628), and Withering's Account of the Foxglove (1785) — are named in the article as historical sources rather than as modern citations. Links open at the publisher, DOI, or PubMed (National Library of Medicine) in a new tab.

Hajar R. Congestive heart failure: a history. Heart Views. 2019;20(3):129-132. — doi:10.4103/HEARTVIEWS.HEARTVIEWS_77_19 (PMID: 31620262)
Davis RH. Bloodletting as a cure for dropsy: heart failure down the ages. Journal of Cardiac Failure / historical review. — PubMed: bloodletting, dropsy, and the history of heart failure
Ancient Egyptian medicine and the concept of heart failure. Journal of Cardiac Failure (historical review). — PubMed: ancient Egyptian medicine and heart failure
Ribatti D. William Harvey and the discovery of the circulation of the blood. Journal of Angiogenesis Research. 2009;1:3. — doi:10.1186/2040-2384-1-3
Aird WC. Discovery of the cardiovascular system: from Galen to William Harvey. Journal of Thrombosis and Haemostasis. 2011;9(Suppl 1):118-129. — doi:10.1111/j.1538-7836.2011.04312.x
Withering W (1785) and the foxglove — historical and pharmacological reviews of digitalis. — PubMed: Withering, foxglove, and the history of digitalis
Norn S, Kruse PR. Cardiac glycosides: from foxglove to digitalis — a historical review (digitalis from Withering onward). — PubMed: digitalis and cardiac glycosides, historical review
Zimmer HG. Who discovered the Frank-Starling mechanism? News in Physiological Sciences. 2002;17:181-184. — PubMed: who discovered the Frank–Starling mechanism?
Katz AM. Ernest Henry Starling, his predecessors, and the “Law of the Heart.” Circulation. 2002;106(23):2986-2992. — doi:10.1161/01.CIR.0000040594.96123.55
Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. Journal of the American College of Cardiology. 1992;20(1):248-254. — doi:10.1016/0735-1097(92)90167-L
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure (CONSENSUS). New England Journal of Medicine. 1987;316(23):1429-1435. — doi:10.1056/NEJM198706043162301
Ibn al-Nafis and the discovery of the pulmonary circulation — historical reviews. — PubMed: Ibn al-Nafis and the pulmonary circulation
The history and evolution of heart-failure management — overview reviews. — PubMed: history and evolution of heart-failure management
Avicenna (Ibn Sina), the Canon of Medicine, and cardiology in medieval Islamic medicine. — PubMed: Avicenna, the Canon of Medicine, and cardiology

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents